多家创新药企在2025年上半年交出了亮眼的业绩报告,标志着行业正从依赖国内市场和仿制药模式向以原始创新和全球注册为核心的新阶段转变。甘李药业实现营收20.67亿元,同比增长57.18%,净利润6.04亿元,同比增长101.96%;百济神州首次半年度实现盈利,归母净利润4.50亿元,主要得益于自主研发产品如百悦泽®和安进授权产品的销售增长;乐普生物预计上半年利润不少于2400万元,首次实现盈利,收入...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.